[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Peanut Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 136 pages | ID: P032FBE011A6EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Peanut Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Drugs In Development, 2022, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 8, 3, 1, 9 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 4 molecules, respectively.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Peanut Allergy - Overview
Peanut Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Peanut Allergy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peanut Allergy - Companies Involved in Therapeutics Development
Peanut Allergy - Drug Profiles
Peanut Allergy - Dormant Projects
Peanut Allergy - Discontinued Products
Peanut Allergy - Product Development Milestones
Featured News & Press Releases
Jul 03, 2022: Aimmune Therapeutics to present new data for PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022
Jul 01, 2022: Allergy Therapeutics showcases allergy immunotherapy leadership at Congress of the European Academy of Allergy and Clinical Immunology (EAACI) 2022
Jun 27, 2022: ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy
Jun 22, 2022: Intrommune announces expanded scope of phase 1 OMEGA study in adults with peanut allergy
Jun 01, 2022: Intrommune Therapeutics names Nandini Murthy as head of regulatory
May 16, 2022: Prota Therapeutics achieves 51 percent peanut allergy remission rate, first company to validate significant quality of life improvements compared with standard care
May 11, 2022: Intrommune previews Phase II trial design for peanut allergy toothpaste
Apr 25, 2022: Allergy Therapeutics shares positive data on VLP Peanut at the 2022 WAO-BSACI Conference
Apr 06, 2022: INT301 continues to meet safety goals in phase 1 omega study in adults with peanut allergy while reaching phase 2 target maintenance dose
Mar 04, 2022: Aravax opens IND for PVX108 Phase 2 trials and strengthens SAB
Mar 01, 2022: Allergy Therapeutics shares positive new data at the 2022 American Academy of Allergy Asthma and Immunology Annual Meeting
Feb 16, 2022: Aimmune Therapeutics announces publication of pooled safety analysis of PALFORZIA treatment for up to 2 years in the Journal of Allergy and Clinical Immunology
Feb 09, 2022: Prota Therapeutics achieves peanut allergy treatment milestone: groundbreaking clinical trial data demonstrates clinical remission of peanut allergy in paediatric patients
Feb 08, 2022: Intrommune reports positive update from ongoing phase 1 study in peanut allergy
Jan 26, 2022: Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Peanut Allergy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Peanut Allergy - Pipeline by Aimmune Therapeutics Inc, 2022
Peanut Allergy - Pipeline by ALK-Abello AS, 2022
Peanut Allergy - Pipeline by Allakos Inc, 2022
Peanut Allergy - Pipeline by Allergy Therapeutics Plc, 2022
Peanut Allergy - Pipeline by Angany Inc, 2022
Peanut Allergy - Pipeline by Aravax Pty Ltd, 2022
Peanut Allergy - Pipeline by AstraZeneca Plc, 2022
Peanut Allergy - Pipeline by BioLingus AG, 2022
Peanut Allergy - Pipeline by BlueWillow Biologics Inc, 2022
Peanut Allergy - Pipeline by Cambridge Allergy Ltd, 2022
Peanut Allergy - Pipeline by Cour Pharmaceuticals Development Co Inc, 2022
Peanut Allergy - Pipeline by DBV Technologies SA, 2022
Peanut Allergy - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Peanut Allergy - Pipeline by IgGenix Inc, 2022
Peanut Allergy - Pipeline by Inimmune Corp, 2022
Peanut Allergy - Pipeline by InnoUp Farma SL, 2022
Peanut Allergy - Pipeline by Intrommune Therapeutics Inc, 2022
Peanut Allergy - Pipeline by Mabylon AG, 2022
Peanut Allergy - Pipeline by Moonlight Therapeutics Inc, 2022
Peanut Allergy - Pipeline by Novartis AG, 2022
Peanut Allergy - Pipeline by Phlaxis, 2022
Peanut Allergy - Pipeline by Prota Therapeutics Pty Ltd, 2022
Peanut Allergy - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Peanut Allergy - Pipeline by Sementis Ltd, 2022
Peanut Allergy - Pipeline by Ukko Inc, 2022
Peanut Allergy - Pipeline by Vedanta Biosciences Inc, 2022
Peanut Allergy - Pipeline by Virtici LLC, 2022
Peanut Allergy - Dormant Projects, 2022
Peanut Allergy - Discontinued Products, 2022

LIST OF FIGURES

Number of Products under Development for Peanut Allergy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022


More Publications